| 5.96 0.23 (4.01%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.31  |
1-year : | 8.54 |
| Resists | First : | 6.26 |
Second : | 7.31 |
| Pivot price | 4.83 |
|||
| Supports | First : | 4.78 |
Second : | 3.86 |
| MAs | MA(5) : | 5.58 |
MA(20) : | 4.7 |
| MA(100) : | 4.34 |
MA(250) : | 0 | |
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 85 |
D(3) : | 82.1 |
| RSI | RSI(14): 75.3 |
|||
| 52-week | High : | 8.38 | Low : | 1.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CALC ] has closed below upper band by 5.6%. Bollinger Bands are 46.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.27 - 6.29 | 6.29 - 6.31 |
| Low: | 5.46 - 5.49 | 5.49 - 5.51 |
| Close: | 5.92 - 5.95 | 5.95 - 5.99 |
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Wed, 24 Apr 2024
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis - PR Newswire
Wed, 24 Apr 2024
BML Capital Management LLC Acquires 56643 Shares of CalciMedica, Inc. (NASDAQ:CALC) - Defense World
Wed, 03 Apr 2024
CalciMedica And 2 Other Penny Stocks Insiders Are Buying - RENN Fund (AMEX:RCG), CalciMedica (NASDAQ:CALC) - Benzinga
Wed, 13 Mar 2024
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI ... - PR Newswire
Wed, 28 Feb 2024
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th ... - PR Newswire
Tue, 13 Feb 2024
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe ... - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 14.8 (%) |
| Held by Institutions | 53 (%) |
| Shares Short | 37 (K) |
| Shares Short P.Month | 21 (K) |
| EPS | -7.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.41 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -176.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.78 |
| PEG Ratio | 0 |
| Price to Book value | 4.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|